葛根素注射剂致急性溶血性贫血临床分析  

Clinical detection of acute hemolytic anemia due to puerarin

作　　者：邓培媛[1] 张俊[1] 朱玉珍[2] 张京航[1] 李群娜[1] 裴振峨[1] 

机构地区：[1]北京市药品不良反应监测中心,北京100024 [2]北京大学第一医院,北京100034

出　　处：《中国新药杂志》2004年第8期751-753,共3页Chinese Journal of New Drugs

摘　　要：目的:探讨葛根素注射剂(GGS)引起急性溶血性贫血(Hemolytic Anemia,HA)的不良反应的发生机制、临床特征和影响因素。方法:以北京市药品不良反应监测中心主持的《葛根素不良反应及影响因素研究》课题葛根素暴露组和其研究期前后发生溶血性贫血的10例为研究对象进行总结。采用血液免疫学体外药物模拟抗球蛋白试验检测患者体内抗葛根素药物性抗体(GGS-Ab)。结果:GGS引起的HA属于Ⅱ型变态反应。通过对使用葛根素注射剂的患者进行血红蛋白浓度、网织红细胞计数和尿常规等指标监测,可早期发现可疑HA病例并经采取及时停药措施即可痊愈,以避免严重和死亡病例的发生,GGS-Ab检测可明确诊断。结论:对于使用GGS的患者应定期监测相关指标,特别是对于体内已存在GGS-Ab的患者应避免再次使用该药。Objective:To explore the pathogenesis and clinical detection of acute hemolytic anemia (HA) due to puerarin (GGS).Methods: 10 puerarin patients that experienced the HA ADR were recruited in this study.The Coomb's tests were used to detect antibodies to puerarin (GGS-Ab) in the recruited patients. Results:HA induced by puerarin is classified as type Ⅱ hypersensitivity reaction. By closely monitoring laboratory values in hemoglobin,reticulocyte counts and urine tests,early identification of potential HA events is possible,and the early detection can prevent patients from serious ADRs and deaths by prompt termination of dosing puerarin. Conclusion:During dose titration of GGS,the GGS-Ab should be frequently monitored. The patients with GGS-Ab should not be given with puerarin.

关 键 词：葛根素 溶血性贫血 药物不良反应 

分 类 号：R556.62[医药卫生—血液循环系统疾病] R284.1[医药卫生—内科学]